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Background: The epidermal growth factor receptor (EGFR) is a promising therapeutic target 
in cancer, but its clinical value in breast cancer remains controversial. Our previous studies 
have found that quantitative analysis of biomarkers with quantum dot-based nanotechnology 
had better detection performance than conventional immunohistochemistry. The present study 
was undertaken to investigate the prognostic value of EGFR in breast cancer using quantum 
dot-based quantitative spectral analysis.
Methods: EGFR expression in 65 breast cancer specimens was detected by immunohis-
tochemistry and quantum dot-immunohistochemistry, and comparisons were made between 
the two methods. EGFR expression in tissue microarrays of 240 breast cancer patients was 
then detected by quantum dot-immunohistochemistry and spectral analysis. The prognostic 
value of EGFR immunofluorescence area (EGFR area) for five-year recurrence-free survival 
was investigated.
Results: The same antigen localization, high correlation of staining rates (r = 0.914), and 
high agreement of measurement (κ = 0.848) of EGFR expression in breast cancer were found 
by quantum dot-immunohistochemistry and immunohistochemistry. The EGFR area showed 
significant differences by tumor grade, lymph node status, HER2 status, and hormone receptor 
status (all P , 0.05). Patients in the large EGFR area ($30.51) group had a significantly higher 
five-year recurrence rate (47.2% versus 27.4%, P = 0.002) and worse five-year recurrence-free 
survival (log-rank test, P = 0.0015) than those in the small EGFR area (,30.51) group. In the 
subgroups, EGFR area was an independent prognosticator in the HER2-positive and lymph 
node-positive subgroups.
Conclusion: Quantum dot-based quantitative detection demonstrates the prognostic value 
of EGFR area in the HER2-positive and lymph node-positive subgroups of invasive breast 
cancer.
Keywords: quantum dots, breast cancer, epidermal growth factor receptor, quantitative analysis, 
recurrence-free survival, prognosis
Introduction
Breast cancer is the most common cancer in women, both in terms of incidence and 
mortality.1 Understanding its biological behavior and identifying objective prog-
nosticators and biologic targets could help improve the outcome. The epidermal 
growth factor receptor (EGFR) is a member of the ErbB receptor family and is a 
new therapeutic target in solid tumors.2 To date, four members of the ErbB receptor 
family have been identified, including EGFR (HER1/ErbB-1), HER2 (ErbB-2/neu), 
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HER3 (ErbB-3), and HER4 (ErbB-4). These ErbB receptors 
are widely expressed in several mammalian tissues and cell 
types, particularly those of epithelial, mesenchymal, and 
neuronal origin. They participate actively in physiological 
functions, such as cell proliferation and differentiation, cell–
cell interaction, cytokine signaling and stress responses, and 
in oncological activities, such as cancer cell proliferation, 
survival, and metastasis.2,3 Structurally, EGFR is a trans-
membrane protein with an extracellular epidermal growth 
factor-binding domain, a transmembrane region, and an 
intracellular domain with ligand-activated tyrosine kinase 
activity. EGFR has been identified as a key cell surface 
receptor involved in a complex signaling network, with a 
binding capacity to various classes of agonists, including 
epidermal growth factor, transforming growth factor alpha, 
heparin-binding epidermal growth factor-like growth factor, 
amphiregulin, epiregulin, epigen, betacellulin, and neuregulin 
2β.4 The clinical value of EGFR in breast cancer remains 
controversial.5–9 Some researchers have demonstrated a sig-
nificant negative impact of EGFR overexpression on both 
relapse-free survival and overall survival,5–7 while others have 
failed to establish such a link.8,9 The causes for discrepan-
cies among these studies may not only be due to differences 
in sample size and durations of follow-up, but also due to 
use of differing analytical procedures with different cutoff 
levels. Currently, the most commonly used method to detect 
EGFR in breast cancer specimens is immunohistochemistry. 
This conventional staining method may not be appropriate 
to investigate the role of EGFR in breast cancer because of 
its technical shortcomings, such as being prone to interfer-
ing factors, unstable sensitivity, high discrepancy between 
laboratories, and subjective interpretation.9,10
Quantum dots are semiconductor nanocrystals with a 
core/shell structure and a large spectral band gap, with unique 
photodynamic properties such as size-tunable symmetric 
emission bands, strong light absorbance, high fluorescent 
intensity, and high photostability.11 Quantum dot fluorescence 
can be separated from background autofluorescence in bio-
logical specimens, including cells and tissues.12 These prop-
erties facilitate integration of nanotechnology and biology, 
contributing to major advances in medical   diagnostics, 
targeted therapeutics, and cellular and molecular biological 
studies.11–13 Notably, bioconjugation of quantum dots with 
functional molecules like antigens and antibodies offers a new 
pathway to enhanced sensing and imaging technologies.13 
Our previous study of molecular targeted imaging of cancer 
cells and molecules14–16 has demonstrated the advantages 
of quantum dot-based molecular pathology, such as higher 
fluorescent efficiency over organic fluorescent dyes, better 
signal clarity, and a higher sensitivity and   accuracy   compared 
with conventional immunohistochemistry   techniques. 
Therefore, quantum dot-based nanotechnology opens a new 
window to gain better insights into tumor   biology. This 
study was undertaken to investigate the prognostic value of 
EGFR in breast cancer using quantum dot-based quantitative 
nanotechnology and spectrum analysis.
Materials and methods
Patients and specimens
Complete information on the clinicopathological characteris-
tics of patients and fabrication of tissue microarrays has been 
detailed in our previous study.16 Briefly, tumor   specimens from 
240 patients aged 29–78 (median 48) years with invasive breast 
cancer were collected from Hubei Cancer Hospital, Wuhan, 
China, from January 2002 to December 2006. Two tissue 
cores representing two different invasive areas were obtained 
for each specimen, giving 480 cores for 240 specimens. Seven 
tissue microarray blocks were constructed, six containing 
70 cores and one containing 60 cores. Consecutive sections 
(4 µm in thickness) of the tissue microarray blocks were cut to 
make tissue microarray slides. Major pathological parameters 
were available, including tumor size, location and number, 
lymph node status,   histological grade, hormone receptor 
status, and HER2 status, as determined by conventional 
immunohistochemistry. All the patients were on a regular 
follow-up schedule. Written informed consent was obtained 
from the patients, and the study protocol was approved by 
the ethics committee.
The primary end point was recurrence-free survival, 
defined as the time interval from breast cancer surgery to 
the first evidence of recurrence (local, regional, or distant).16 
If without recurrence, patients were censored on the last 
follow-up. In this study, we only selected the five-year data 
for analysis.
EGFR testing
The antibodies were purchased from Zhongshan Golden 
Bridge Biotechnology Co Ltd, Beijing, China. The primary 
antibody was rabbit antihuman monoclonal antibody against 
EGFR (clone SP9, 1:120 dilution) and the control group 
antibody was rabbit IgG (1:120 dilution). Biotinylated goat 
antirabbit IgG (1:400 dilution) was the secondary antibody. 
The three-step avidin-biotin-horseradish peroxidase complex 
method (ABC, MaiXin Bio Co Ltd, Fuzhou, China) was 
used for immunohistochemistry. A quantum dot-conjugated 
streptavidin probe (1:200 dilution) with a 605 nm emission 
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wavelength was obtained from Wuhan Jiayuan Quantum 
Dots Co Ltd, Wuhan, China.
Quantum dot-immunohistochemistry was similar 
to conventional immunohistochemistry, with the major 
procedures described in our previous study,14–16 includ-
ing the following brief steps: deparaffinizing → antigen 
retrieval → blocking → primary antibody (rabbit IgG for 
control group) → washing → blocking → biotinylated 
secondary antibody → washing → blocking → quantum 
dot-conjugated streptavidin probes → washing → mount-
ing and observation.
This study was divided into two parts, ie, a feasibility 
study and a confirmation study. In the feasibility study, 
65 specimens randomly selected from 240 breast cancer 
specimens were detected by both conventional immunohis-
tochemistry and quantum dot-immunohistochemistry. One 
hundred tumor cells from five representative fields of each 
specimen at high magnification (400×) were counted for 
EGFR-positive cells. The EGFR positivity rates detected by 
quantum dot-immunohistochemistry and immunohistochem-
istry staining were compared. In the confirmation study, 
quantum dot-based immunofluorescent imaging of EGFR 
was conducted using the 605 nm quantum dot-conjugated 
streptavidin probe on the abovementioned tissue microarray 
slides. The slides were examined under an Olympus BX51 
fluorescence microscope equipped with an Olympus DP72 
camera (Olympus Optical Co Ltd, Tokyo, Japan) and a 
multispectral imaging Nuance system (Cambridge Research 
and Instrumentation Inc, Woburn, MA). The 605 quantum 
dots were excited by blue light (excitation wavelength 
450–480 nm). Images of the quantum dots were captured 
using a DP72 camera. The spectral cube for each core of 
tissue microarray containing complete spectral information 
at 10 nm wavelength intervals from 520 to 680 nm was col-
lected by the Nuance system. All the cubes were captured 
under the same conditions at low magnifications (40×), 
because this technique could obtain the entire images for 
each core, making it more accurate and representative in 
the tumor marker assay. Quantum dot fluorescence signal 
information for every core was analyzed by the analysis 
software package (Nuance version 2.8) within the Nuance 
system.
EGFR fluorescence signals and distribution area in 
the tumor were calculated numerically based on spectral 
unmixing. The distribution area of internal cytokeratin 
imaging was measured using the same method and condi-
tions as in our previous study,16 and defined as the total 
area of tumor cells. The ratio of EGFR distribution area to 
cytokeratin area was calculated and defined as a percentage 
of EGFR-positive area. The EGFR area was calculated by 
the following equation:
EGFR area =   acquired total fluorescence areas of EGFR  
÷ total fluorescence areas of cytokeratin  
× 100
The acquired total fluorescence areas of EGFR were 
defined as the sum of EGFR fluorescence areas on the two 
cores of tissue microarray.
Statistical analysis
The Spearman’s rho correlation, consistency (κ) check and 
Chi-square test were used to compare the results for quan-
tum dot-immunohistochemistry and immunohistochemistry. 
Differences in EGFR areas were assessed using the Mann–
Whitney U test or Kruskal–Wallis H test. Receiver-operating 
characteristic (ROC) curve analysis was conducted to 
evaluate the predictive value of the EGFR area for five-year 
recurrence-free survival. The optimal point with the highest 
sum value of sensitivity and specificity was defined as the 
cutoff. The Kaplan–Meier method was used to assess for 
differences in five-year recurrence-free survival. A multivari-
ate Cox regression model was used to select independent 
predictors of five-year recurrence-free survival. Statistical 
analyses were performed using SPSS 13.0 software (SPSS 
Inc, Chicago, IL). Two-tailed P , 0.05 was considered to be 
statistically significant.
Results
EGFR expression in feasibility study
In the feasibility study, EGFR expression was observed on 
the same location on the membranes and in the cytoplasm 
by quantum dot-immunohistochemistry (Figure 1A) and 
immunohistochemistry (Figure 1B). The isotype control 
group (rabbit IgG) did not show any positive expression 
on breast cancer cells (Figure 1C and D). EGFR staining 
rates detected by quantum dot-immunohistochemistry 
and immunohistochemistry were 0%–85% and 0%–82%, 
respectively. Median EGFR staining rates by quantum 
dot-immunohistochemistry and immunohistochemistry 
were 15% (25%–75% interquartile range, 8%–38.5%) 
and 13% (25%–75% interquartile range, 5%–35.5%), 
  respectively. Spearman’s rho correlation analysis showed 
that the correlation coefficient of EGFR staining rates 
by the two methods was 0.914. According to the EGFR 
  PharmaDx Interpretation Manual,17 with a EGFR staining 
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was evaluated. EGFR area was significantly correlated with 
lymph node status, hormone receptor status, HER2 status, 
and tumor grading. No significant relationship was found 
between EGFR area and the other clinicopathological fea-
tures (Table 1).
ROC analysis of EGFR area by five-year 
recurrence-free survival
ROC analysis of EGFR area by five-year recurrence is shown 
in Figure 3A, which indicates that the quantum dot-based 
EGFR area could predict five-year recurrence. According 
to the optimal sensitivity and specificity of the ROC curve 
by five-year recurrence status, 30.51 were defined as the 
optimal cutoff for EGFR area, with sensitivity of 65.9% and 
specificity of 55%.
Figure  1  EGFR  expression  on  breast  cancer  cells  by  quantum  dot- 
immunohistochemistry  and  immunohistochemistry.  EGFR-positive  expression  on 
breast cancer cells imaged under Olympus DP72 camera (400×) by quantum dot- 
immunohistochemistry (A) and immunohistochemistry (B), control group (rabbit 
IgG) showed no any positive expression on breast cancer cells by quantum dot- 
immunohistochemistry (C), and immunohistochemistry (D). Scale bar: 25 µm for 
(A, B, C, and D). 
Abbreviation: EGFR, epidermal growth factor receptor.
AB
CD
E F
GH
0.0
Wavelength (nm)
520
540
560
580
600
620
640
660
680
0.2
0.4
0.6
0.8
1.0
Figure 2 EGFR determination and quantitative analysis. EGFR positive expression 
(A) and EGFR-negative expression (B) imaged under DP72 camera (40×); EGFR 
signal distribution (C) and EGFR signal locating (D) in the core (40×) unmixed by the 
Nuance multispectral imaging system; EGFR-positive expression imaged under DP72 
camera (200×) (E), EGFR signal analysis by Nuance multispectral imaging systems 
(F), EGFR positive expression (G) and negative control group (H) imaged under 
DP72 camera (400×). Scale bar: 250 µm for (A–D), 50 µm for (E), 25 µm for   
(G and H). 
Abbreviation: EGFR, epidermal growth factor receptor.
rate of 30% set as cutoff, 20 (30.8%) cases were positive 
by quantum   dot-immunohistochemistry and 19 (29.2%) 
cases were positive by immunohistochemistry (P = 0.848). 
Of 65 cases, 19 cases were concurrently positive by two 
methods (κ = 0.848, consistency check). Both methods 
revealed the same antigen distribution and measurement 
consistency. These results suggest that quantum dot- 
immunohistochemistry had performance equal to that of 
conventional immunohistochemistry.
EGFR area in 240 cases
Among 240 breast cancer specimens, EGFR expression 
was observed in 235 tumors (Figure 2A, E, and G), and 
five tumors did not show any EGFR signal (Figure 2B). 
Quantum dot signals of EGFR were obtained from cubes 
by spectral unmixing (Figure 2C, D, and F). The control 
group showed no EGFR expression (Figure 2H). The EGFR 
total fluorescence areas of the 235 samples ranged from 
171 to 176,629. The median EGFR area of all the breast 
cancer patients was 33.08 (25%–75% interquartile range, 
11.79–59.77), after adjustment for the area of cytokeratin 
(internal control).
Relationship between EGFR area  
and clinicopathological features
The association between EGFR area and major clinicopatho-
logical features, including age, tumor size, lymph node status, 
tumor grade, hormone receptor status, and HER2 status 
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EGFR area and five-year recurrence-free 
survival
In this study, the five-year recurrence rate was 37.9% 
(91/240), with 20 local recurrences and 71 distant recurrences. 
Based on the cutoff value of 30.51 for EGFR fluorescence 
area, the 240 breast cancer tumors were classified into two 
subgroups, ie, tumors with a small EGFR area (,30.51, 
n = 113) and those with a large EGFR area ($30.51, n = 127). 
The five-year recurrence rate was 47.2% in patients with a 
large EGFR area, and 27.4% in those with a small EGFR 
area (P = 0.002). The five-year recurrence-free survival of 
the two groups showed a significant difference (P = 0.0015, 
log-rank test, Figure 3B).
Univariate analysis indicated that lymph node status, 
tumor grade, tumor size, HER2 status, EGFR area, and 
hormone receptor status had significant correlations with 
five-year recurrence-free survival (all P , 0.05, Table 2). 
However, among all the above factors, multivariate   analysis 
using a Cox regression model revealed that only lymph 
node status, tumor size, tumor grade, and HER2 status were 
  independent prognosticators, whereas the other factors, 
including EGFR area, were not in the equation.
The 240 patients were further classified into subgroups 
according to lymph node status, tumor size, HER2 status, and 
hormone receptor status. Univariate analysis and multivariate 
analysis indicated that EGFR area was an independent 
  prognosticator in the lymph node-positive and HER2-positive 
subgroups (Table 2), whereas in other subgroups, EGFR area 
did not enter into the equation of multivariate analysis.
Five-year recurrence rate and recurrence-free survival 
were investigated in the HER2 and lymph node subgroups. 
The differences in five-year recurrence rate and recurrence-
free survival between patients with a large EGFR area and 
a small EGFR area in the HER2-negative and lymph node-
negative subgroups did not reach statistical significance (both 
P . 0.05, Figure 4A and B).
Table  1  Main  clinicopathological  features  and  EGFR  area  of   
240 patients with breast cancer
Items n (%) EGFR area,  
median (IQR)
P value
Age (years)
 # 50 149 (62.1) 32.28 (11.91, 59.09) 0.927a
 . 50 91 (37.9) 34.82 (11.72, 60.76)
Tumor size (cm)
  T1 (T # 2) 35 (14.6) 24.46 (4.71, 55.23) 0.102b
  T2 (2 , T # 5) 162 (67.5) 30.90 (7.57, 63.49)
  T3 (T . 5) 43 (17.9) 41.33 (27.50, 59.94)
Lymph node status
  Positive 131 (54.6) 37.81 (15.43, 65.90) 0.009a
  Negative 109 (45.4) 24.04 (5.29, 55.31)
Tumor grade
  Grade 1 40 (16.7) 29.70 (9.12, 59.35) 0.031b
  Grade 2 141 (58.8) 26.16 (6.18, 58.84)
  Grade 3 59 (24.6) 45.31 (27.50, 62.45)
HR status
  Positive 152 (63.3) 29.28 (6.74, 58.03) 0.049a
  Negative 88 (36.7) 44.02 (14.47, 65.73)
HER2 status
  Positive 123 (51.3) 46.61 (17.42, 66.35) 0.040a
  Negative 117 (48.7) 29.04 (9.41, 58.59)
Notes: aMann–Whitney U test; bKruskal–Wallis H test.
Abbreviations: EGFR, epidermal growth factor receptor; HR, hormone receptor; 
IQR, interquartile range.
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Figure 3 Receiver-operating characteristic analysis of EGFR area by five-year recurrent status of 240 cases (A) and the five-year recurrence-free survival of patients with 
different EGFR area (B). 
Abbreviation: EGFR, epidermal growth factor receptor.
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In the HER2-positive subgroup, the five-year recurrence 
rate was 55.7% (39/70) in patients with a large EGFR area 
and 34.0% (18/53) in those with a small area (P = 0.017). 
The median five-year recurrence-free survival in patients 
with a large EGFR area was 41.0 months (95% confidence 
interval [CI] 16.4–65.6 months), but the median five-year 
recurrence-free survival in those with small EGFR area was 
not reached yet (P = 0.0098, log-rank test, Figure 4C). In 
the lymph node-positive subgroup, the five-year recurrence 
rate was 65.8% (52/79) in patients with a large EGFR 
area and 42.3% (22/52) in those with a small EGFR area 
(P = 0.008). The median five-year recurrence-free survival 
was 34.0 months (95% CI 19.9–28.1) in patients with a large 
EGFR area, but was not reached in those with a small EGFR 
area (P = 0.0079, log-rank, Figure 4D).
Discussion
In this study, quantum dot-immunohistochemistry showed 
good correlation and consistency with conventional 
immunohistochemistry in detecting EGFR, and better 
image quality and sensitivity than conventional immu-
nohistochemistry in detecting biomarkers, as previously 
reported.14   Taking advantage of the optical properties of   
quantum dots, which   overcome the limitations associated 
with tissue autofluorescence, allow accurate determination 
of biomarkers, and quantify the   biomarkers because of 
sharper and more photostable fluorescent signals of quantum 
dots than organic dyes,11–13 we quantified the expression of 
EGFR in breast cancer specimens using a quantum dot-
based immunofluorescence probe. From a new perspective, 
ie, the EGFR fluorescence area, we investigated the prog-
nostic value of EGFR in breast cancer. Patients with a large 
EGFR area demonstrated a significantly higher five-year 
recurrence rate and worse recurrence-free survival. It was 
a prognostic predictor of five-year recurrence-free survival 
for the entire study population in univariate analysis, but 
not in multivariate analysis. However, in the HER2-positive 
and lymph node-positive subgroups, EGFR area was an 
independent prognostic predictor both in univariate analysis 
and multivariate analysis.
The prognostic significance of EGFR in breast cancer 
has been investigated for over 20 years, yet no agreement 
has been reached. Sainsbury et al5 investigated 139 patients 
with breast cancer and found that recurrence-free survival 
and overall survival were significantly worse for patients 
with EGFR-positive tumors compared with EGFR-negative 
tumors, that EGFR was the most important variable in 
  predicting recurrence-free survival and overall survival in 
Table 2 Factors correlated with five-year recurrence-free survival of patients with breast cancer
Patient group Univariate analysis Multivariate analysis
Wald P RR 95% CI Wald P RR 95% CI
Lower Upper Lower Upper
Total cases (n = 240)
  Age 0.204 0.652 1.102 0.724 1.677 NE NE NE NE NE
  Grade 61.983 0.000 4.439 3.063 6.433 30.419 0.000 3.074 2.062 6.045
  Lymph node status 35.862 0.000 5.035 2.966 8.545 20.555 0.000 3.512 2.040 6.323
  Tumor size 24.190 0.000 2.542 1.753 3.686 5.283 0.022 1.547 1.066 2.246
  HER2 status 18.255 0.000 2.603 1.678 4.038 5.034 0.025 1.218 1.025 1.448
  HR status 12.799 0.000 0.472 0.313 0.712 NE NE NE NE NE
  EGFR area 9.576 0.002 1.984 1.286 3.063 NE NE NE NE NE
Lymph node-positive subgroup (n = 131)
  Age 0.005 0.946 1.016 0.639 1.616 NE NE NE NE NE
  Grade 23.691 0.000 2.879 1.888 4.447 16.688 0.000 2.428 1.586 3.716
  Tumor size 10.134 0.001 1.900 1.280 2.820 NE NE NE NE NE
  HER2 status 25.065 0.000 3.367 2.093 5.416 18.599 0.000 2.897 1.787 4.699
  HR status 20.782 0.000 0.342 0.216 0.543 NE NE NE NE NE
  EGFR area 6.654 0.010 1.930 1.171 3.182 5.174 0.023 1.789 1.084 2.953
HER2-positive subgroup (n = 123)
  Age 0.802 0.371 1.274 0.750 2.162 NE NE NE NE NE
  Grade 34.649 0.000 4.256 2.627 6.893 13.277 0.000 2.507 1.529 4.110
  Tumor size 6.296 0.011 1.900 1.155 3.125 NE NE NE NE NE
  Lymph node status 27.219 0.000 9.624 4.111 22.532 16.738 0.000 6.316 2.612 15.272
  HR status 7.501 0.006 0.474 0.277 0.809 NE NE NE NE NE
  EGFR area 6.269 0.012 2.044 1.168 3.578 4.495 0.034 1.843 1.047 3.245
Abbreviations: RR, relative risk; NE, not in the equation; HR, hormone receptor; EGFR, epidermal growth factor receptor; CI, confidence interval.
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lymph node-negative patients, and that this was the second 
most important variable in lymph node-positive patients. 
However, Ferrero et al8 investigated 780 consecutive breast 
cancer patients using a specific ligand-binding assay and found 
that there was no link between tumor size, grade, node status, 
and EGFR tumor levels. There was a constant and   significant 
decrease in EGFR tumor levels according to patient age, and 
a significant inverse relationship between estrogen receptor 
status and EGFR. Tsutsui et al9 investigated 1029 patients 
with primary breast cancer by immunohistochemistry and 
found that EGFR was an independent prognostic factor for 
recurrence-free survival and overall survival in all patients, 
but the value of EGFR was somewhat insufficient to achieve 
statistical significance for both recurrence-free survival and 
overall survival in the subgroups according to nodal status. 
These confusing and even contradictory findings justify the 
need to re-evaluate EGFR using other molecular methods in 
different patient populations.
With the recent advances in biomedical science,   targeted 
therapies and personalized medicine hold the future in 
clinical practice. EGFR has been studied from different 
perspectives and has been considered as a new therapeutic 
target in solid tumors. Cetuximab, gefitinib, erlotinib, and 
lapatinib17–22 are agents targeting the EGFR pathway, and 
have been approved for the treatment of advanced colorec-
tal cancer, squamous cell carcinoma of the head and neck, 
advanced non-small cell lung cancer, pancreatic cancer, and 
breast cancer,23 which has led investigators to restudy EGFR 
from different perspectives.24
In the ErbB family, HER2 is the most extensively studied 
member, and its overexpression is closely correlated with 
aggressive behavior and poor prognosis of breast cancer. 
The relationship between EGFR and HER2 in breast cancer 
has been extensively investigated. Recently, McIntyre et al25 
investigated all receptors and ligands in the ErbB family using 
immunohistochemistry and found that the heterogeneity in 
expression of receptor and ligands was unexpectedly high, 
with HER2 ranking first and EGFR ranking second. Yonemori 
et al26 investigated the immunohistochemistry expression 
of EGFR, HER3, and HER4 in HER2-positive patients 
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Figure 4 The EGFR area and five-year recurrence-free survival in HER2 and lymph node subgroups. 
Abbreviations: EGFR, epidermal growth factor receptor; LN, lymph node.
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with breast cancer treated with trastuzumab-containing 
neoadjuvant chemotherapy, and found that only EGFR was 
a negative prognosticator of pathologic complete response in 
this HER2-positive population. With regard to the mechanism, 
one study reported that both EGFR and HER2 act synergisti-
cally to cause aberrant tumor growth, leading to early onset 
of metastasis and death.27 Overexpression of HER2 can 
potentiate EGFR signaling and contribute to EGFR-mediated 
transformation and tumor progression.28 Further, HER2/
EGFR heterodimers showed ineffective endocytosis and 
destruction of ligand-bound EGFR, in contrast with EGFR 
homodimers.29 Breast cancer with coexpression of EGFR and 
HER2 has been shown to have the worst prognosis, whereas 
the prognostic value of HER2 was stronger than that of EGFR 
in breast cancer.30 In accordance with these reports, our study 
confirmed that HER2 was an independent prognosticator 
of breast cancer. EGFR and HER2 had additive adverse 
effects on prognosis. Patients with both positive HER2 and 
a large EGFR area had worse recurrence-free survival, and a 
large EGFR area significantly increased five-year recurrence 
rate by 21.7% compared with a small EGFR area. Therefore, 
we suggest that simultaneous detection of HER2 and EGFR 
could improve the predictive value and enable better treatment 
decisions. Quantum dot-based concurrent labeling technology 
provides such potential.31
Lymph node status is an important prognostic predic-
tor of breast cancer. We observed that the EGFR area was 
significantly higher in our lymph node-positive subgroup 
than in our lymph node-negative subgroup. In the lymph 
node-positive subgroup, a large EGFR area significantly 
increased five-year recurrence rate by 23.5% comparing with 
a small EGFR area. In patients with simultaneous lymph 
node positivity and a large EGFR area, the median five-year 
recurrence-free survival was only 34.0 months, which implies 
that EGFR detection was more meaningful in patients with 
lymph node-positive breast cancer.
A couple of studies have reported a significant inverse 
relationship between EGFR and hormone receptor status.5,6,8 
Consistent with these reports, we also observed an inverse 
relationship between EGFR area and hormone receptor 
status, and the EGFR area was significantly higher in the 
hormone receptor-negative group than in the hormone 
receptor-positive group.
This study has several limitations. First, it was a retro-
spective study using a nonrandomized database. Second, it 
included only 240 patients with breast cancer, and the median 
follow-up was only five years, so the results may have been 
more accurate with a larger sample size and longer follow up. 
Third, the treatment was not controlled, and we assumed that 
all 240 patients with breast cancer received optimal treatment 
after surgery, which might have introduced some bias in the 
results. Nevertheless, quantum dot-based nanotechnology 
provides a new insight into this elusive biomarker.
In conclusion, quantum dot-immunohistochemistry 
demonstrated a performance at least equivalent to that of 
immunohistochemistry in detecting EGFR in breast cancer 
specimens. Quantitative analysis with quantum   dot-based 
technology indicated that EGFR area has a negative 
  prognostic value in patients with HER2-positive and lymph 
node-positive breast cancer.
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